Vaxart, INC Form 4 insider transactions

Vaxart Director W. Mark Watson acquired 10,000 shares of common stock, signaling increased confidence in the company's future.

Vaxart, Inc. Director Kevin Finney reported the acquisition of 6,103 common shares and 36,392 stock options through equity grants on June 13, 2025, as part of his compensation.

Vaxart, Inc. Director W. Mark Watson was granted 16,000 shares of common stock and options to purchase 95,400 shares, with vesting tied to the 2026 annual meeting or June 13, 2026.

Vaxart, Inc. Director Elaine J. Heron reported the acquisition of 16,000 common shares and 95,400 stock options through equity grants, increasing her beneficial ownership in the company.

Vaxart, Inc. Director David E. Wheadon has reported the acquisition of 16,000 shares of common stock from restricted stock unit vesting and a grant of 95,400 stock options, signaling an increase in his beneficial ownership.

Vaxart, Inc. Director Michael J. Finney has reported the acquisition of 16,000 common shares and 95,400 stock options as part of an equity compensation grant, with vesting scheduled for mid-2026.

Jeroen Nicolaas Grasman, CFO of Vaxart, Inc., reports the acquisition of stock options and restricted stock units.

Vaxart's CEO, Steven Lo, indirectly acquired 100,000 shares of common stock through The Lo Family Trust at a price of $0.49 per share on May 19, 2025.

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports a transaction involving the withholding of shares to cover income tax obligations related to vested RSUs.

Sean Tucker, SVP and Chief Scientific Officer of Vaxart, Inc., reports a transaction involving the withholding of shares to cover income tax obligations related to vested RSUs.

Vaxart's CEO, Steven Lo, reports the acquisition of shares and options in the company, signaling potential confidence in its future.

Sean Tucker, SVP, Chief Scientific Officer of Vaxart, Inc., reports acquiring 406,000 shares of common stock and being granted options to purchase 610,000 shares.

Phillip E. Lee, CFO of Vaxart, Inc., reports the acquisition of 406,000 shares of common stock and 610,000 stock options on March 24, 2025.

Chief Medical Officer of Vaxart, James F. Cummings, reports acquiring shares and stock options in the company.

Edward Berg, SVP and General Counsel of Vaxart, Inc., reports the acquisition of shares and stock options, as well as the disposal of shares, in a recent SEC filing.

Edward Berg, SVP and General Counsel of Vaxart, Inc., reports the withholding of 8,050 common stock shares to cover income tax obligations related to vested RSUs.

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports the withholding of shares to cover tax obligations and shares acquired under the Employee Stock Purchase Plan.

Vaxart's CEO, Steven Lo, disposed of 22,362 shares to cover income tax obligations related to vested RSUs.

Vaxart's SVP, Chief Scientific Officer Sean Tucker, reports the disposal of shares to cover income tax withholding obligations related to vested RSUs.

Phillip E. Lee, CFO of Vaxart, Inc., reports the withholding of shares to cover income tax obligations related to vested RSUs.

Sean Tucker, SVP and Chief Scientific Officer of Vaxart, Inc., reports the withholding of shares to cover income tax obligations related to vested RSUs.

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports the withholding of 7,964 common stock shares to cover tax obligations related to vested RSUs on February 2, 2025.

Edward Berg, SVP and General Counsel of Vaxart, Inc., reported disposing of 9,242 shares of common stock to cover income tax obligations related to vested RSUs.

Vaxart director Kevin Finney acquired 32,000 shares of common stock and 190,800 stock options on January 28, 2025, as part of his compensation.

Vaxart's Chief Financial Officer, Phillip E. Lee, reported the withholding of 6,132 common shares to cover tax obligations related to vested Restricted Stock Units (RSUs).

Vaxart director W. Mark Watson purchased 20,000 shares of common stock at a price of $0.6789 per share on June 18, 2024.

Phillip E. Lee, CFO of Vaxart, Inc., reports the withholding of 2,007 common stock shares to cover income tax obligations related to vested RSUs.

Director David Wheadon reports acquisition of 16,000 common stock shares and 95,400 stock options in Vaxart, Inc.

Director Michael J. Finney reports acquisition of 16,000 shares of common stock and 95,400 stock options in Vaxart, Inc.

Director Elaine J. Heron reports acquisition of 16,000 shares of common stock and 95,400 stock options in Vaxart, Inc.